287 related articles for article (PubMed ID: 8667431)
1. Altered pharmacokinetics of vinblastine in Mdr1a P-glycoprotein-deficient Mice.
van Asperen J; Schinkel AH; Beijnen JH; Nooijen WJ; Borst P; van Tellingen O
J Natl Cancer Inst; 1996 Jul; 88(14):994-9. PubMed ID: 8667431
[TBL] [Abstract][Full Text] [Related]
2. Comparative pharmacokinetics of vinblastine after a 96-hour continuous infusion in wild-type mice and mice lacking mdr1a P-glycoprotein.
van Asperen J; van Tellingen O; Schinkel AH; Beijnen JH
J Pharmacol Exp Ther; 1999 Apr; 289(1):329-33. PubMed ID: 10087021
[TBL] [Abstract][Full Text] [Related]
3. Homozygous disruption of the mdrla P-glycoprotein gene affects blood-nerve barrier function in mice administered with neurotoxic drugs.
Saito T; Zhang ZJ; Ohtsubo T; Noda I; Shibamori Y; Yamamoto T; Saito H
Acta Otolaryngol; 2001 Sep; 121(6):735-42. PubMed ID: 11678173
[TBL] [Abstract][Full Text] [Related]
4. Multidrug resistance-reversing agents increase vinblastine distribution in normal tissues expressing the P-glycoprotein but do not enhance drug penetration in brain and testis.
Arboix M; Paz OG; Colombo T; D'Incalci M
J Pharmacol Exp Ther; 1997 Jun; 281(3):1226-30. PubMed ID: 9190857
[TBL] [Abstract][Full Text] [Related]
5. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein.
Sikic BI; Fisher GA; Lum BL; Halsey J; Beketic-Oreskovic L; Chen G
Cancer Chemother Pharmacol; 1997; 40 Suppl():S13-9. PubMed ID: 9272128
[TBL] [Abstract][Full Text] [Related]
6. Resolution of P-glycoprotein and non-P-glycoprotein effects on drug permeability using intestinal tissues from mdr1a (-/-) mice.
Stephens RH; O'Neill CA; Bennett J; Humphrey M; Henry B; Rowland M; Warhurst G
Br J Pharmacol; 2002 Apr; 135(8):2038-46. PubMed ID: 11959808
[TBL] [Abstract][Full Text] [Related]
7. Conferone from Ferula schtschurowskiana enhances vinblastine cytotoxicity in MDCK-MDR1 cells by competitively inhibiting P-glycoprotein transport.
Barthomeuf C; Demeule M; Grassi J; Saidkhodjaev A; Beliveau R
Planta Med; 2006 Jun; 72(7):634-9. PubMed ID: 16739070
[TBL] [Abstract][Full Text] [Related]
8. Tissue disposition, excretion and metabolism of vinblastine in mice as determined by high-performance liquid chromatography.
van Tellingen O; Beijnen JH; Nooijen WJ; Bult A
Cancer Chemother Pharmacol; 1993; 32(4):286-92. PubMed ID: 8324870
[TBL] [Abstract][Full Text] [Related]
9. Disruption of mdr1a p-glycoprotein gene results in dysfunction of blood-inner ear barrier in mice.
Zhang ZJ; Saito T; Kimura Y; Sugimoto C; Ohtsubo T; Saito H
Brain Res; 2000 Jan; 852(1):116-26. PubMed ID: 10661503
[TBL] [Abstract][Full Text] [Related]
10. Functional characterization of a glycine 185-to-valine substitution in human P-glycoprotein by using a vaccinia-based transient expression system.
Ramachandra M; Ambudkar SV; Gottesman MM; Pastan I; Hrycyna CA
Mol Biol Cell; 1996 Oct; 7(10):1485-98. PubMed ID: 8898356
[TBL] [Abstract][Full Text] [Related]
11. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins.
Schinkel AH; Mayer U; Wagenaar E; Mol CA; van Deemter L; Smit JJ; van der Valk MA; Voordouw AC; Spits H; van Tellingen O; Zijlmans JM; Fibbe WE; Borst P
Proc Natl Acad Sci U S A; 1997 Apr; 94(8):4028-33. PubMed ID: 9108099
[TBL] [Abstract][Full Text] [Related]
12. What kinds of substrates show P-glycoprotein-dependent intestinal absorption? Comparison of verapamil with vinblastine.
Ogihara T; Kamiya M; Ozawa M; Fujita T; Yamamoto A; Yamashita S; Ohnishi S; Isomura Y
Drug Metab Pharmacokinet; 2006 Jun; 21(3):238-44. PubMed ID: 16858128
[TBL] [Abstract][Full Text] [Related]
13. Inhibitory effect of cyclosporin A on p-glycoprotein function in peripheral nerves of mice treated with doxorubicin and vinblastine.
Saito T; Zhang ZJ; Ohtsubo T; Noda I; Tokuriki M; Shibamori Y; Yamamoto T; Saito H
Acta Otolaryngol; 2004 Apr; 124(3):313-7. PubMed ID: 15141761
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of P-glycoprotein transport function and reversion of MDR1 multidrug resistance by cnidiadin.
Barthomeuf C; Grassi J; Demeule M; Fournier C; Boivin D; Béliveau R
Cancer Chemother Pharmacol; 2005 Aug; 56(2):173-81. PubMed ID: 15824923
[TBL] [Abstract][Full Text] [Related]
15. P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans.
Schuetz EG; Schinkel AH; Relling MV; Schuetz JD
Proc Natl Acad Sci U S A; 1996 Apr; 93(9):4001-5. PubMed ID: 8633005
[TBL] [Abstract][Full Text] [Related]
16. Functional studies of P-glycoprotein in inside-out plasma membrane vesicles derived from murine erythroleukemia cells overexpressing MDR 3. Properties and kinetics of the interaction of vinblastine with P-glycoprotein and evidence for its active mediated transport.
Schlemmer SR; Sirotnak FM
J Biol Chem; 1994 Dec; 269(49):31059-66. PubMed ID: 7983045
[TBL] [Abstract][Full Text] [Related]
17. Regulation of initial vinblastine influx by P-glycoprotein.
Shalinsky DR; Jekunen AP; Alcaraz JE; Christen RD; Kim S; Khatibi S; Howell SB
Br J Cancer; 1993 Jan; 67(1):30-6. PubMed ID: 8094005
[TBL] [Abstract][Full Text] [Related]
18. Screening of multidrug-resistance sensitive drugs by in situ brain perfusion in P-glycoprotein-deficient mice.
Cisternino S; Rousselle C; Dagenais C; Scherrmann JM
Pharm Res; 2001 Feb; 18(2):183-90. PubMed ID: 11405289
[TBL] [Abstract][Full Text] [Related]
19. Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdr1a P-glycoprotein.
van Asperen J; van Tellingen O; Tijssen F; Schinkel AH; Beijnen JH
Br J Cancer; 1999 Jan; 79(1):108-13. PubMed ID: 10408701
[TBL] [Abstract][Full Text] [Related]
20. Contribution of P-glycoprotein to bunitrolol efflux across blood-brain barrier.
Matsuzaki J; Yamamoto C; Miyama T; Takanaga H; Matsuo H; Ishizuka H; Kawahara Y; Kuwano M; Naito M; Tsuruo T; Sawada Y
Biopharm Drug Dispos; 1999 Mar; 20(2):85-90. PubMed ID: 10206323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
